George Freeman, who had held the role spanning both the Department of Health and the Department for Business, Innovation and Skills since 2014, has moved up into a key position within the new UK government, to chair the Prime Minister’s Policy Board. His elevation is already being felt by the country's life sciences community which is bracing for huge change and uncertainty after the June 23 referendum's surprise vote to leave the European Union.
Freeman’s portfolio as undersecretary included the government's controversial Cancer Drugs Fund, the National Health Service's digital drive, genomics, life sciences industrial strategy, and pursuing the uptake of new drugs and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?